The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a 3-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.
The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles.
In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease.
Optimizing and personalizing the approach to salvage therapy remains an ongoing area of work in the field of genitourinary oncology and represents an area of research and clinical care that requires well-coordinated, multi-disciplinary efforts.
The Journal of urology. 2024 Feb 14 [Epub ahead of print]
Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, Erin Kirkby, Amy N Luckenbaugh, Ben J Nathanson, Yaw A Nyame, Edwin M Posadas, Phuoc T Tran, Ronald C Chen
Urology, University of Michigan., Urology, Mayo Clinic., Radiation Oncology, Stanford University., Urology, University of Texas MD Anderson Cancer Center., Urology, Fox Chase Cancer Center-Temple Health., Radiology, Harvard University., Pacific Northwest Evidence-based Practice Center., Radiation Oncology, Massachusetts General Hospital, Harvard Medical School., American Urological Association., Urology, Vanderbilt University., Division of Hematology and Oncology Medicine, University of Washington., Urologic Oncology, Cedars Sinai., Radiation Oncology, University of Maryland., Radiation Oncology, University of Kansas.